GE Achieves Record Transmission of Power on a Super Energy Highway in India
14.11.2019 14:59:00 EET | Business Wire | Press release
GE’s Grid Solutions business (NYSE:GE) announced today a new milestone in its Champa-Kurukshetra ultra-high-voltage direct current (UHVDC) project in India with the 1,305-km link now capable of transmitting 4,500 MW of electricity. This follows the recent successful energization of the third of four poles planned for the ±800kV UHVDC transmission line.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005360/en/
Inside the Valve Hall of the Champa-Kurukshetra HVDC Converter Station, image courtesy of GE (Photo: Business Wire)
A special feature of the Champa project is the use of an overhead line with dedicated metallic return, which uses a neutral conductor as a part of the DC circuit. GE is the first company in the world to demonstrate this technology with this project and is therefore providing additional value to the customer by eliminating the typical technical and environmental issues associated with the traditional electrode solution.
The transmission line is a crucial component of the Indian government’s electricity-for-all initiative and will help provide reliable electricity for millions of people living in the states of Punjab, Haryana, Delhi, Uttar Pradesh and surrounding areas. The project is being executed by GE T&D India Limited, the listed entity of GE’s Grid Solutions business in India.
New government initiatives and robust private-sector investments have reversed India’s longstanding power deficit. With the growing renewable energy market, the nation now boasts an installed capacity of over 360 gigawatts (GW), making it the third-largest electricity producer in the world. However, to meet the government’s vision of power-to-all and to ensure last mile connectivity, continuous development of a robust transmission network is vital for the country.
Power Grid Corporation of India Ltd (POWERGRID), India’s largest state-owned transmission company, is helping address this issue by connecting the power deficit northern Indian region with power surplus regions of eastern India using GE’s UHVDC technology.
“Thanks to this latest milestone in the GE Champa-Kurukshetra project, India is now transmitting more electricity over this link than any other DC link in India, helping to resolve the supply shortfalls in the north. This project also includes an integration where two separately designed bi-poles are running in parallel operation over the same DC transmission line, a design feature only seen on two other HVDC projects in the world, both of which GE was involved with, a great compliment to our legacy and current HVDC controls capability. On behalf of everyone at GE’s Grid Solutions, I would like to thank our teams in India and our UK HVDC center of excellence for this remarkable feat,” said Rajendra Iyer, head of Grid Integrated Solutions at GE’s Grid Solutions. The Grid Integration Solutions division, comprised of High Voltage Direct Current (HVDC) and FACTS technologies, designs and integrates transmission solutions that help meet the world’s ever-evolving power needs.
The Champa-Kurukshetra project transmits electricity from power generating plants located across Chhattisgarh, a state in eastern region of India, to a GE-built rectifier station in Champa, where it is converted from alternating current (AC) to direct current (DC). The electricity is transported in bulk across the UHVDC line and is then converted back to AC by a GE inverter station in Kurukshetra, Haryana. From there, power is transported to the surrounding rural states who are in need of reliable and consistent electrical power. DC technology efficiently moves electricity over long distances which lowers transmission costs and losses. Additionally, it is a more environment-friendly technology because it requires fewer overhead lines to deliver the same amount of power as a high-voltage AC system.
Phase 1 of the project, completed in 2017, provided 3,000 MW of transmission capacity. GE’s recent energization of Pole 3 added another 1,500 MW of transmission capacity, marking a key benchmark towards the completion of Phase 2. Once Pole 4 is commissioned, the entire system will transmit 6,000 MW of electricity at 800kV - making the project one of the largest generation-to-consumption transmission systems in the world.
Notes to Editors:
About GE T&D India Limited:
GE T&D is the listed entity of GE’s Grid Solutions business in India. With over 100 years of presence in India, GE T&D India is a leading player in the Power Transmission & Distribution business with a product portfolio ranging from Medium Voltage to Ultra High Voltage (1,200 kilovolt) for Power Generation, Transmission and Distribution, Industry and Infrastructure markets.
GE T&D India has a significant presence in all stages of the power supply chain and offers a wide range of products that include Power Transformers, Circuit Breakers, Gas Insulated Switchgears, Instrument Transformers, Substation Automation Equipment. Digital Software Solutions, Turnkey Solutions for Substation Engineering & Construction, Flexible AC Transmission Systems, High Voltage DC & Services suite of offerings. With six manufacturing sites, GE T&D India is future ready to meet the growing demands for equipment and services. GE is focused towards on introducing Green and Digital Solutions aimed towards making the Indian Grid smarter and more environmentally-friendly.
About GE’s Grid Solutions:
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. For more about GE Renewable Energy’s Grid Solutions business, visit www.gegridsolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005360/en/
Contact information
For media queries, please contact:
Anshul Madaan
Communications Leader
GE Grid Solutions – South Asia
anshul.madaan@ge.com
Allison J. Cohen
GE Renewable Energy, Grid Solutions business
External Communications Manager
+972-(0)54-7299742
allison.j.cohen@ge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom